{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:09:13Z","timestamp":1790359753944,"version":"4.1.0"},"reference-count":23,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2021,2,17]]},"abstract":"<jats:p>\n                    Lenacapavir (LEN; GS-6207) is a potent first-in-class inhibitor of HIV-1 capsid with long-acting properties and the potential for subcutaneous dosing every 3\u2009months or longer. In the clinic, a single subcutaneous LEN injection (20\u2009mg to 750\u2009mg) in people with HIV (PWH) induced a strong antiviral response, with a &gt;2.3 mean log\n                    <jats:sub>10<\/jats:sub>\n                    decrease in HIV-1 RNA at day 10.\n                  <\/jats:p>","DOI":"10.1128\/aac.02057-20","type":"journal-article","created":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T08:55:45Z","timestamp":1607417745000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":69,"title":["Absence of Lenacapavir (GS-6207) Phenotypic Resistance in HIV Gag Cleavage Site Mutants and in Isolates with Resistance to Existing Drug Classes"],"prefix":"10.1128","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0911-4237","authenticated-orcid":true,"given":"Nicolas","family":"Margot","sequence":"first","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee","family":"Ram","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Rhee","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Callebaut","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro3490"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2014.02.004"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.2174\/1568026615666150902102143"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0560-x"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2443-1"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa060"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.3390\/v2071411"},{"key":"e_1_3_3_9_2","volume-title":"HIV-1 Gag polymorphisms determine treatment response to bevirimat (PA-457)","author":"McCallister S","year":"2008","unstructured":"McCallister S, Lalezari J, Richmond G, Thompson M, Harrigan R, Martin D, Salzwedel K, Allaway G. 2008. HIV-1 Gag polymorphisms determine treatment response to bevirimat (PA-457). XVII International HIV Drug Resistance Workshop, Sitges, Spain."},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2234683100"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01369-06"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.70.6.3763-3769.1996"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.2.589-594.2001"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.71.9.6662-6670.1997"},{"key":"e_1_3_3_15_2","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1177\/135965350601100708","article-title":"Compensatory mutations at the HIV cleavage sites p7\/p1 and p1\/p6-gag in therapy-naive and therapy-experienced patients","volume":"11","author":"Verheyen J","year":"2006","unstructured":"Verheyen J, Litau E, Sing T, Daumer M, Balduin M, Oette M, Fatkenheuer G, Rockstroh JK, Schuldenzucker U, Hoffmann D, Pfister H, Kaiser R. 2006. Compensatory mutations at the HIV cleavage sites p7\/p1 and p1\/p6-gag in therapy-naive and therapy-experienced patients. Antivir Ther 11:879\u2013887.","journal-title":"Antivir Ther"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040036"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000345"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M108005200"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01784-09"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02560-15"},{"key":"e_1_3_3_21_2","volume-title":"Measurement of maturation inhibitor susceptibility using the PhenoSenseHIV assay, poster 880","author":"Choe SS","year":"2008","unstructured":"Choe SS, Feng Y, Limoli K, Salzwedel K, McCallister S, Huang W, Parkin NT. 2008. Measurement of maturation inhibitor susceptibility using the PhenoSenseHIV assay, poster 880. 15th Conference on Retroviruses and Opportunistic Infections (CROI), Boston, MA."},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.12.2781"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.44.4.920-928.2000"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2011.12.008"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02057-20","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02057-20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T04:18:36Z","timestamp":1670041116000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02057-20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,17]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,2,17]]}},"alternative-id":["10.1128\/AAC.02057-20"],"URL":"https:\/\/doi.org\/10.1128\/aac.02057-20","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,17]]},"assertion":[{"value":"2020-09-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02057-20"}}